Zeroing in on Merck rival, GSK steps up to the FDA with its top new vaccine prospect
Just weeks after GlaxoSmithKline lined up a slate of promising Phase III data for its shingles vaccine Shingrix, the pharma giant has filed its pitch with the FDA in search of an approval that could generate some substantial revenue.
GlaxoSmithKline investigators have patiently amassed considerable data for this product. The two-dose vaccine posted a 90% efficacy rate among patients over 70 in one big Phase III that tracked patients for 4 years. The pooled data from two late-stage studies hit 89% for people over 70 and 91% for those over 50.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.